Certolizumab pegol: in Crohn's disease
Stephanie K A Blick1, Monique P Curran
1Wolters Kluwer Health / Adis, Auckland, New Zealand. demail@adis.co.nz
Summary
Certolizumab pegol effectively treats moderate to severe Crohn's disease. This anti-tumor necrosis factor-alpha therapy, administered subcutaneously every four weeks, demonstrated good tolerability in clinical trials.
Area of Science:
- Immunology
- Gastroenterology
- Pharmacology
Background:
- Tumor necrosis factor-alpha (TNFalpha) plays a key role in inflammatory conditions like Crohn's disease.
- Developing targeted therapies to neutralize TNFalpha is crucial for managing inflammatory bowel disease.
Purpose of the Study:
- To evaluate the efficacy and safety of certolizumab pegol as a treatment for moderate to severe Crohn's disease.
- To assess the long-term effectiveness and tolerability of certolizumab pegol in a patient population with elevated C-reactive protein levels.
Main Methods:
- Two randomized, double-blind, placebo-controlled Phase III trials were conducted.
- Patients received certolizumab pegol (400mg every 4 weeks, with an additional dose at week 2) or placebo.
- Efficacy was assessed based on clinical response and remission criteria, with C-reactive protein levels monitored.
Main Results:
- Certolizumab pegol demonstrated significant efficacy in inducing and maintaining remission in patients with moderate to severe Crohn's disease.
- Patients treated with certolizumab pegol showed a notable reduction in inflammatory markers.
- The drug was generally well-tolerated, with most adverse events being mild to moderate in nature. No cases of lupus were reported.
Conclusions:
- Certolizumab pegol is an effective and well-tolerated therapeutic option for moderate to severe Crohn's disease.
- The pegylated Fab' fragment offers an extended half-life, allowing for convenient subcutaneous administration.
- This anti-TNFalpha therapy represents a valuable advancement in the management of inflammatory bowel disease.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...